Emerging Immunotherapy Options for Metastatic NSCLC – OncLive
OncLive |
Emerging Immunotherapy Options for Metastatic NSCLC
OncLive I’m not sure we will reach really better data giving only immunotherapy checkpoint inhibitors. But then you have combination of checkpoints plus chemotherapy, and you have the combination of checkpoint and checkpoint, so CTLA-4 and anti-PD-1 or anti-PD … |
Seeking Alpha |
FDA designates Omeros’ OMS721 for accelerated review for stem cell transplant-associated clotting disorder; shares …
Seeking Alpha Omeros (OMER +9.3%) is up on modestly higher volume in response to its announcement that the FDA has designated lead candidate OMS721 a Breakthrough Therapy for the treatment of patients with high-risk hematopoietic stem cell transplant-associated … FDA Grants Breakthrough Therapy Designation to Omeros’ MASP-2 Inhibitor OMS721 for the Treatment of High-Risk …Business Wire (press release) |
OncLive |
Expert Covers Burgeoning Role of CAR T-Cell Therapy in Myeloma
OncLive Chimeric antigen receptor (CAR) T-cell therapy has demonstrated potential for patients with relapsed/refractory multiple myeloma, and improvements in efficacy and safety may facilitate its transition into earlier-stage settings, says Maung Myo Htut, MD. What’s the Total Cost of One CAR T-Cell Treatment? – MedscapeMedscape CAR-T 2.0? A split, universal and programmable system …FierceBiotech Analysis determines true cost for CAR T-cell therapy – HealioHealio Endpoints News –Medical Xpress all 8 news articles » |